thymine has been researched along with Liver Neoplasms in 45 studies
Liver Neoplasms: Tumors or cancer of the LIVER.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Regorafenib and TAS-102 are standard treatment options in refractory metastatic colorectal cancer based on improvement in overall survival by 6 and 8 weeks, respectively, when compared with best supportive care alone (BSC)." | 9.27 | Cost-effectiveness Analysis of Regorafenib and TAS-102 in Refractory Metastatic Colorectal Cancer in the United States. ( Barzi, A; Cho, SK; Hay, JW, 2018) |
| "The RECOURSE trial supported trifluridine/tipiracil as a treatment option in metastatic colorectal cancer (mCRC)." | 8.12 | The effect of prognostic factors at baseline on the efficacy of trifluridine/tipiracil in patients with metastatic colorectal cancer: A Portuguese exploratory analysis. ( Basto, R; Bonito, N; Gomes, I; Jacinto, P; Magalhães, J; Paulo, J; Pereira, TC; Sousa, G; Sousa, MJ, 2022) |
| "Although the effectiveness of trifluridine/tipiracil(TFTD)with bevacizumab for unresectable colorectal cancer that was refractory to previous standard chemotherapy was reported, its effectiveness as a first-line treatment, especially for elderly frail patients, is unclear." | 8.02 | [A Case of an Elderly Frail Patient with Unresectable Colorectal Cancer Controlled by Trifluridine/Tipiracil with Bevacizumab Therapy as a First-Line Treatment]. ( Arigami, T; Kita, Y; Kurahara, H; Maemura, K; Matsumoto, R; Mori, S; Natsugoe, S; Sasaki, K; Toda, H, 2021) |
| "This study compared the efficacy of regorafenib and trifluridine/tipiracil (TFTD) in patients with metastatic colorectal cancer (mCRC) who are refractory to standard chemotherapy, because despite their clinical approval, it still remains unclear which of these two drugs should be used as initial treatment." | 7.88 | Propensity Score Analysis of Regorafenib Versus Trifluridine/Tipiracil in Patients with Metastatic Colorectal Cancer Refractory to Standard Chemotherapy (REGOTAS): A Japanese Society for Cancer of the Colon and Rectum Multicenter Observational Study. ( Baba, E; Denda, T; Enomoto, M; Esaki, T; Fukuoka, S; Gosho, M; Ishikawa, T; Kajiwara, T; Kashiwada, T; Komatsu, Y; Kumekawa, Y; Makiyama, C; Moriwaki, T; Okuyama, H; Sakai, D; Satake, H; Shimada, Y; Sugimoto, N; Sugiyama, M; Suto, T; Takashima, A; Tamura, T; Taniguchi, H; Watanabe, T; Yamashita, K; Yamazaki, K, 2018) |
| "Regorafenib and TAS-102 are standard treatment options in refractory metastatic colorectal cancer based on improvement in overall survival by 6 and 8 weeks, respectively, when compared with best supportive care alone (BSC)." | 5.27 | Cost-effectiveness Analysis of Regorafenib and TAS-102 in Refractory Metastatic Colorectal Cancer in the United States. ( Barzi, A; Cho, SK; Hay, JW, 2018) |
| "The RECOURSE trial supported trifluridine/tipiracil as a treatment option in metastatic colorectal cancer (mCRC)." | 4.12 | The effect of prognostic factors at baseline on the efficacy of trifluridine/tipiracil in patients with metastatic colorectal cancer: A Portuguese exploratory analysis. ( Basto, R; Bonito, N; Gomes, I; Jacinto, P; Magalhães, J; Paulo, J; Pereira, TC; Sousa, G; Sousa, MJ, 2022) |
| "Although the effectiveness of trifluridine/tipiracil(TFTD)with bevacizumab for unresectable colorectal cancer that was refractory to previous standard chemotherapy was reported, its effectiveness as a first-line treatment, especially for elderly frail patients, is unclear." | 4.02 | [A Case of an Elderly Frail Patient with Unresectable Colorectal Cancer Controlled by Trifluridine/Tipiracil with Bevacizumab Therapy as a First-Line Treatment]. ( Arigami, T; Kita, Y; Kurahara, H; Maemura, K; Matsumoto, R; Mori, S; Natsugoe, S; Sasaki, K; Toda, H, 2021) |
| "This study compared the efficacy of regorafenib and trifluridine/tipiracil (TFTD) in patients with metastatic colorectal cancer (mCRC) who are refractory to standard chemotherapy, because despite their clinical approval, it still remains unclear which of these two drugs should be used as initial treatment." | 3.88 | Propensity Score Analysis of Regorafenib Versus Trifluridine/Tipiracil in Patients with Metastatic Colorectal Cancer Refractory to Standard Chemotherapy (REGOTAS): A Japanese Society for Cancer of the Colon and Rectum Multicenter Observational Study. ( Baba, E; Denda, T; Enomoto, M; Esaki, T; Fukuoka, S; Gosho, M; Ishikawa, T; Kajiwara, T; Kashiwada, T; Komatsu, Y; Kumekawa, Y; Makiyama, C; Moriwaki, T; Okuyama, H; Sakai, D; Satake, H; Shimada, Y; Sugimoto, N; Sugiyama, M; Suto, T; Takashima, A; Tamura, T; Taniguchi, H; Watanabe, T; Yamashita, K; Yamazaki, K, 2018) |
| "A total of 550 patients with mCRC who were registered in the REGOTAS study (Regorafenib versus TAS-102 as Salvage-line in patients with colorectal cancer refractory to standard chemotherapies: a multicenter observational study, UMIN 000020416) and treated with trifluridine/tipiracil (TFTD) or regorafenib as a later-line therapy were retrospectively stratified according to the modified Glasgow Prognostic Score (mGPS), which divided patients into mGPS 0 to 2 by serum albumin and C-reactive protein, and compared." | 3.88 | Role of Predictive Value of the Modified Glasgow Prognostic Score for Later-line Chemotherapy in Patients With Metastatic Colorectal Cancer. ( Baba, E; Denda, T; Esaki, T; Fukuoka, S; Ishikawa, T; Ito, M; Kajiwara, T; Kashiwada, T; Katsumata, K; Kishimoto, J; Komatsu, Y; Kumekawa, Y; Makiyama, A; Moriwaki, T; Oki, E; Okuyama, H; Sakai, D; Satake, H; Shimada, Y; Sugimoto, N; Suto, T; Takashima, A; Tamura, T; Taniguchi, H; Tsuchihashi, K; Ueno, H; Yamashita, K; Yamazaki, K, 2018) |
| " The favorable safety profile of trifluridine/tipiracil renders it a suitable option to be combined with other local therapies for metastatic lesions." | 1.56 | Trifluridine/tipiracil in combination with local therapy may be a favorable option for refractory metastatic colorectal cancer patients: A case report. ( Lin, BR; Lin, YL; Liu, KL, 2020) |
| " The Grade 3 or worst adverse event that was experienced was neutropenia." | 1.48 | [Safety and Efficacy of TAS-102 with Bevacizumab for the Treatment of Unresectable Metastatic Colorectal Cancer - A Case Report]. ( Arakawa, S; Asano, Y; Horiguchi, A; Imaeda, Y; Isetani, M; Ishihara, S; Ito, M; Ito, R; Kamio, K; Kawabe, N; Kawai, T; Nagata, H; Shimizu, K; Tomishige, H; Yasuoka, H, 2018) |
| "The possibility of interstitial pneumonitis should always be considered when a patient develops a fever and respiratory disorder during treatment containing TAS-102." | 1.48 | [A Case of Interstitial Pneumonitis Induced by TAS-102 for Liver and Lung Metastasis of Colorectal Cancer]. ( Hiramatsu, M; Imai, Y; Kobayashi, T; Kono, E; Sakane, J; Suzuki, Y; Tsunematsu, I, 2018) |
| "We surveyed 47 North American adult hepatocellular carcinomas and three childhood liver tumors for codon 249 mutation." | 1.29 | Mutation at codon 249 of p53 gene in a human hepatoblastoma. ( Carr, BI; Jaffe, R; Kar, S, 1993) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 24 (53.33) | 18.7374 |
| 1990's | 4 (8.89) | 18.2507 |
| 2000's | 1 (2.22) | 29.6817 |
| 2010's | 11 (24.44) | 24.3611 |
| 2020's | 5 (11.11) | 2.80 |
| Authors | Studies |
|---|---|
| Sousa, MJ | 1 |
| Gomes, I | 1 |
| Pereira, TC | 1 |
| Magalhães, J | 1 |
| Basto, R | 1 |
| Paulo, J | 1 |
| Jacinto, P | 1 |
| Bonito, N | 1 |
| Sousa, G | 1 |
| Huwait, E | 1 |
| Awaji, SM | 1 |
| Kumosani, TA | 1 |
| Barbour, EK | 1 |
| Abulnaja, KO | 1 |
| Moselhy, SS | 1 |
| Fujimoto, Y | 1 |
| Nakanishi, R | 1 |
| Nukatsuka, M | 1 |
| Matsuoka, K | 1 |
| Ando, K | 1 |
| Wakasa, T | 1 |
| Kitao, H | 1 |
| Oki, E | 2 |
| Maehara, Y | 1 |
| Mori, M | 1 |
| Lin, YL | 1 |
| Liu, KL | 1 |
| Lin, BR | 1 |
| Matsumoto, R | 1 |
| Mori, S | 1 |
| Toda, H | 1 |
| Kita, Y | 1 |
| Arigami, T | 1 |
| Sasaki, K | 1 |
| Kurahara, H | 1 |
| Maemura, K | 1 |
| Natsugoe, S | 1 |
| Elgemeie, GH | 1 |
| Farag, AB | 1 |
| Suenaga, M | 1 |
| Schirripa, M | 1 |
| Cao, S | 1 |
| Zhang, W | 1 |
| Yang, D | 1 |
| Murgioni, S | 1 |
| Rossini, D | 1 |
| Marmorino, F | 1 |
| Mennitto, A | 1 |
| Ning, Y | 1 |
| Okazaki, S | 1 |
| Berger, MD | 1 |
| Miyamoto, Y | 1 |
| Gopez, R | 1 |
| Barzi, A | 2 |
| Yamaguchi, T | 1 |
| Loupakis, F | 1 |
| Lenz, HJ | 1 |
| Moriwaki, T | 3 |
| Fukuoka, S | 2 |
| Taniguchi, H | 2 |
| Takashima, A | 2 |
| Kumekawa, Y | 2 |
| Kajiwara, T | 2 |
| Yamazaki, K | 3 |
| Esaki, T | 3 |
| Makiyama, C | 1 |
| Denda, T | 3 |
| Satake, H | 2 |
| Suto, T | 2 |
| Sugimoto, N | 3 |
| Enomoto, M | 1 |
| Ishikawa, T | 2 |
| Kashiwada, T | 2 |
| Sugiyama, M | 1 |
| Komatsu, Y | 3 |
| Okuyama, H | 2 |
| Baba, E | 2 |
| Sakai, D | 2 |
| Watanabe, T | 1 |
| Tamura, T | 2 |
| Yamashita, K | 2 |
| Gosho, M | 1 |
| Shimada, Y | 3 |
| Arakawa, S | 1 |
| Horiguchi, A | 1 |
| Tomishige, H | 1 |
| Kawabe, N | 1 |
| Nagata, H | 1 |
| Ishihara, S | 1 |
| Ito, M | 2 |
| Asano, Y | 1 |
| Ito, R | 1 |
| Isetani, M | 1 |
| Shimizu, K | 1 |
| Kamio, K | 1 |
| Kawai, T | 1 |
| Yasuoka, H | 1 |
| Imaeda, Y | 1 |
| Unseld, M | 1 |
| Drimmel, M | 1 |
| Siebenhüner, A | 1 |
| Gleiss, A | 1 |
| Bianconi, D | 1 |
| Kieler, M | 1 |
| Scheithauer, W | 1 |
| Winder, T | 1 |
| Prager, GW | 1 |
| Tsuchihashi, K | 1 |
| Makiyama, A | 1 |
| Katsumata, K | 1 |
| Ueno, H | 1 |
| Kishimoto, J | 1 |
| Yoshino, T | 1 |
| Shinozaki, E | 1 |
| Nishina, T | 1 |
| Baba, H | 1 |
| Tsuji, A | 1 |
| Tsuji, Y | 1 |
| Yamaguchi, K | 1 |
| Muro, K | 1 |
| Takayama, T | 1 |
| Hamamoto, Y | 1 |
| Goto, M | 1 |
| Nakayama, N | 1 |
| Fujii, H | 1 |
| Tanase, T | 1 |
| Ohtsu, A | 1 |
| Cho, SK | 1 |
| Hay, JW | 1 |
| Kono, E | 1 |
| Hiramatsu, M | 1 |
| Kobayashi, T | 1 |
| Tsunematsu, I | 1 |
| Imai, Y | 1 |
| Sakane, J | 1 |
| Suzuki, Y | 1 |
| Lee, MH | 1 |
| Thomas, JL | 1 |
| Chen, JZ | 1 |
| Jan, JS | 1 |
| Lin, HY | 1 |
| Hasegawa, J | 1 |
| Noura, S | 1 |
| Hirota, M | 1 |
| Matsumura, T | 1 |
| Yasuyama, A | 1 |
| Takata, A | 1 |
| Koga, C | 1 |
| Murakami, M | 1 |
| Kameda, C | 1 |
| Oda, N | 1 |
| Kawabata, R | 1 |
| Morishima, H | 1 |
| Shimizu, J | 1 |
| Matsunami, N | 1 |
| POTTER, VR | 6 |
| PITOT, HC | 1 |
| ONO, T | 1 |
| MORRIS, HP | 3 |
| DE VERDIER, CH | 1 |
| ZBARSKY, SH | 1 |
| MORSE, PA | 1 |
| Emura, T | 1 |
| Murakami, Y | 1 |
| Nakagawa, F | 1 |
| Fukushima, M | 1 |
| Kitazato, K | 1 |
| Kar, S | 1 |
| Jaffe, R | 1 |
| Carr, BI | 1 |
| Buckwold, VE | 1 |
| Xu, Z | 1 |
| Yen, TS | 1 |
| Ou, JH | 1 |
| Kramvis, A | 1 |
| Kew, MC | 1 |
| Bukofzer, S | 1 |
| Pontisso, P | 1 |
| Belluco, C | 1 |
| Bertorelle, R | 1 |
| De Moliner, L | 1 |
| Chieco-Bianchi, L | 1 |
| Nitti, D | 1 |
| Lise, M | 1 |
| Alberti, A | 1 |
| Deschamps, Y | 1 |
| Verly, WG | 1 |
| Baliga, BS | 2 |
| Borek, E | 3 |
| Lakings, DB | 1 |
| Waalkes, TP | 1 |
| Gehrke, CW | 1 |
| Mrochek, JE | 1 |
| Longmore, J | 1 |
| Adamson, RH | 1 |
| Huh, NH | 1 |
| Satoh, MS | 2 |
| Shiga, J | 2 |
| Rajewsky, MF | 1 |
| Kuroki, T | 2 |
| Huh, N | 1 |
| Yarosh, DB | 1 |
| Fornace, AJ | 1 |
| Day, RS | 1 |
| Goodman, JI | 2 |
| Zimmerman, M | 1 |
| Sneider, TW | 3 |
| Wolberg, WH | 3 |
| Reddy, R | 1 |
| Ro-Choi, TS | 1 |
| Henning, D | 1 |
| Shibata, H | 1 |
| Choi, YC | 1 |
| Busch, H | 1 |
| Nielsen, HR | 1 |
| Sjolin, KE | 1 |
| Nyholm, K | 1 |
| Wong, R | 1 |
| Queener, SF | 1 |
| Weber, G | 1 |
| Heidelberger, C | 1 |
| Van Way, CW | 1 |
| Reynolds, VH | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Efficacy and Safety of Trifluridine/Tipiracil in Combination With Irinotecan as a Second Line Therapy in Patients With Cholangiocarcinoma[NCT04059562] | Phase 2 | 28 participants (Anticipated) | Interventional | 2021-10-28 | Active, not recruiting | ||
| Phase II Trial of TAS-102 in Patients With Advanced, Refractory Pancreatic Adenocarcinoma[NCT04923529] | Phase 2 | 28 participants (Anticipated) | Interventional | 2021-03-01 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for thymine and Liver Neoplasms
| Article | Year |
|---|---|
Metabolism of thymine in tumor tissue: the origins of beta-aminoisobutyric acid.
Topics: Age Factors; Aminoisobutyric Acids; Animals; Carcinoma, Hepatocellular; Cell Line; DNA; Liver Neopla | 1975 |
Chemical carcinogenesis, chemotherapy: cancer's continuing core challenges--G. H. A. Clowes Memorial Lecture.
Topics: Animals; Antineoplastic Agents; Arginase; Benz(a)Anthracenes; Benzopyrenes; Carcinogens; Cell Divisi | 1970 |
1 trial available for thymine and Liver Neoplasms
| Article | Year |
|---|---|
Cost-effectiveness Analysis of Regorafenib and TAS-102 in Refractory Metastatic Colorectal Cancer in the United States.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Cost-Benefit Analysis; Double- | 2018 |
42 other studies available for thymine and Liver Neoplasms
| Article | Year |
|---|---|
The effect of prognostic factors at baseline on the efficacy of trifluridine/tipiracil in patients with metastatic colorectal cancer: A Portuguese exploratory analysis.
Topics: Aged; Colonic Neoplasms; Colorectal Neoplasms; Female; Humans; Liver Neoplasms; Male; Portugal; Prog | 2022 |
Ruthana date extract inhibited proliferation of human hepatocellular carcinoma (HepG2) cells by modulation of BAX gene.
Topics: Apoptosis; bcl-2-Associated X Protein; Carcinoma, Hepatocellular; Catechols; Cell Proliferation; Fla | 2022 |
Detection of trifluridine in tumors of patients with metastatic colorectal cancer treated with trifluridine/tipiracil.
Topics: Animals; Apoptosis; Cell Proliferation; Colorectal Neoplasms; Drug Combinations; Humans; Liver Neopl | 2020 |
Trifluridine/tipiracil in combination with local therapy may be a favorable option for refractory metastatic colorectal cancer patients: A case report.
Topics: Adenocarcinoma; Aged; Drug Combinations; Humans; Liver Neoplasms; Male; Neoplasm Staging; Peritoneal | 2020 |
[A Case of an Elderly Frail Patient with Unresectable Colorectal Cancer Controlled by Trifluridine/Tipiracil with Bevacizumab Therapy as a First-Line Treatment].
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorectal Neo | 2021 |
Design, synthesis, and in vitro anti-hepatocellular carcinoma of novel thymine thioglycoside analogs as new antimetabolic agents.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Proliferation; Drug Design; Drug Screening As | 2017 |
Genetic variants of DNA repair-related genes predict efficacy of TAS-102 in patients with refractory metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Colorectal Neoplasms; Disease-Free Survival; | 2017 |
Propensity Score Analysis of Regorafenib Versus Trifluridine/Tipiracil in Patients with Metastatic Colorectal Cancer Refractory to Standard Chemotherapy (REGOTAS): A Japanese Society for Cancer of the Colon and Rectum Multicenter Observational Study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone | 2018 |
[Safety and Efficacy of TAS-102 with Bevacizumab for the Treatment of Unresectable Metastatic Colorectal Cancer - A Case Report].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Drug Combinations; Humans; Liver | 2018 |
Optimizing Treatment Sequence for Late-line Metastatic Colorectal Cancer Patients Using Trifluridine/Tipiracil and Regorafenib.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Administration Schedule; | 2018 |
Role of Predictive Value of the Modified Glasgow Prognostic Score for Later-line Chemotherapy in Patients With Metastatic Colorectal Cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; C-Reactive Protein; Colorec | 2018 |
Relationship Between Thymidine Kinase 1 Expression and Trifluridine/Tipiracil Therapy in Refractory Metastatic Colorectal Cancer: A Pooled Analysis of 2 Randomized Clinical Trials.
Topics: Aged; Antineoplastic Agents; Colorectal Neoplasms; Drug Combinations; Drug Resistance, Neoplasm; Fem | 2018 |
[A Case of Interstitial Pneumonitis Induced by TAS-102 for Liver and Lung Metastasis of Colorectal Cancer].
Topics: Aged; Drug Combinations; Humans; Liver Neoplasms; Lung Diseases, Interstitial; Lung Neoplasms; Male; | 2018 |
Activation of tumor suppressor p53 gene expression by magnetic thymine-imprinted chitosan nanoparticles.
Topics: Apoptosis; Chitosan; Gene Transfer Techniques; Genes, p53; Hep G2 Cells; Humans; Liver Neoplasms; Na | 2016 |
[A Case of Metastatic Colorectal Cancer Refractory to Standard Chemotherapies Treated with TAS-102 with Bevacizumab].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Combined Modality Therapy; Drug Combina | 2016 |
The comparative enzymology and cell origin of rat hepatomas. I. Deoxycytidylate deaminase and thymine degradation.
Topics: Amidohydrolases; Animals; Carcinoma, Hepatocellular; DCMP Deaminase; Liver Neoplasms; Liver Neoplasm | 1960 |
Alternative pathways of thymine and uracil metabolism in the liver and hepatoma.
Topics: Carcinoma, Hepatocellular; Humans; Liver; Liver Neoplasms; Thymine; Uracil | 1960 |
THE EFFECT OF ACTINOMYCIN D ON THE INCORPORATION OF C14-FORMATE INTO NUCLEIC ACIDS OF EHRLICH ASCITES CARCINOMA AND NOVIKOFF HEPATOMA IN VITRO.
Topics: Adenine; Animals; Ascites; Carbon Isotopes; Carcinoma, Ehrlich Tumor; Carcinoma, Hepatocellular; Dac | 1964 |
PYRIMIDINE METABOLISM IN TISSUE CULTURE CELLS DERIVED FROM RAT HEPATOMAS. I. SUSPENSION CELL CULTURES DERIVED FROM THE NOVIKOFF HEPATOMA.
Topics: Animals; Carcinoma, Hepatocellular; Cell Culture Techniques; Floxuridine; Fluorouracil; Glycine; Liv | 1965 |
A novel antimetabolite, TAS-102 retains its effect on FU-related resistant cancer cells.
Topics: Animals; Antimetabolites; Antimetabolites, Antineoplastic; Cell Line, Tumor; Colorectal Neoplasms; C | 2004 |
A novel antimetabolite, TAS-102 retains its effect on FU-related resistant cancer cells.
Topics: Animals; Antimetabolites; Antimetabolites, Antineoplastic; Cell Line, Tumor; Colorectal Neoplasms; C | 2004 |
A novel antimetabolite, TAS-102 retains its effect on FU-related resistant cancer cells.
Topics: Animals; Antimetabolites; Antimetabolites, Antineoplastic; Cell Line, Tumor; Colorectal Neoplasms; C | 2004 |
A novel antimetabolite, TAS-102 retains its effect on FU-related resistant cancer cells.
Topics: Animals; Antimetabolites; Antimetabolites, Antineoplastic; Cell Line, Tumor; Colorectal Neoplasms; C | 2004 |
Mutation at codon 249 of p53 gene in a human hepatoblastoma.
Topics: Adolescent; Adult; Carcinoma, Hepatocellular; Child; Codon; DNA, Viral; Genes, p53; Guanine; Humans; | 1993 |
Effects of a frequent double-nucleotide basal core promoter mutation and its putative single-nucleotide precursor mutations on hepatitis B virus gene expression and replication.
Topics: Adenine; Base Sequence; Biological Factors; Carcinoma, Hepatocellular; Gene Expression Regulation, V | 1997 |
Hepatitis B virus precore mutants in serum and liver of Southern African Blacks with hepatocellular carcinoma.
Topics: Adult; Amino Acid Sequence; Base Sequence; Black People; Carcinoma, Hepatocellular; Codon, Terminato | 1998 |
Hepatitis C virus infection associated with human hepatocellular carcinoma: lack of correlation with p53 abnormalities in Caucasian patients.
Topics: Adenine; Aged; Carcinoma, Hepatocellular; Codon; Cohort Studies; DNA, Viral; Exons; Female; Genes, p | 1998 |
The hepatic chalone. II. Chemical and biological properties of the rabbit liver chalone.
Topics: Aging; Animals; Carcinoma, Hepatocellular; Cell Division; Cell Survival; Cells, Cultured; Deoxyribon | 1975 |
Composition, associated tissue methyltransferase activity, and catabolic end products of transfer RNA from carcinogen-induced hepatoma and normal monkey livers.
Topics: Animals; Carcinoma, Hepatocellular; Diethylnitrosamine; Female; Guanine; Guanosine; Haplorhini; Hypo | 1977 |
Immunoanalytical detection of O4-ethylthymine in liver DNA of individuals with or without malignant tumors.
Topics: Adolescent; Adult; Aged; Alkylation; Chromatography, High Pressure Liquid; DNA; Female; Humans; Live | 1989 |
Detection of O4-ethylthymine in human liver DNA.
Topics: Deoxyguanosine; DNA; Environmental Monitoring; Humans; Liver; Liver Neoplasms; Radioimmunoassay; Thy | 1988 |
Human O6-alkylguanine-DNA alkyltransferase fails to repair O4-methylthymine and methyl phosphotriesters in DNA as efficiently as does the alkyltransferase from Escherichia coli.
Topics: Alkylation; Cell Line; Cells, Cultured; Colonic Neoplasms; DNA Repair; Escherichia coli; HeLa Cells; | 1985 |
The effect of 5-fluorodeoxyuridine on the synthesis of deoxyribonucleic acid pyrimidines in precancerous rat liver.
Topics: Aminohydrolases; Animals; Carbon Isotopes; Carcinogens; Cell Nucleus; Cytosine; DNA; Floxuridine; In | 1973 |
Selective inhibition by deoxyglucosyl thymine of thymidine phosphorylases not catalyzing deoxyribosyl transfer.
Topics: Animals; Bone Marrow; Carcinoma 256, Walker; Carcinoma, Ehrlich Tumor; Carcinoma, Hepatocellular; Gl | 1964 |
Enzymes of thymidine triphosphate synthesis in selected Morris hepatomas.
Topics: Aminohydrolases; Animals; Carcinoma, Ehrlich Tumor; Carcinoma, Hepatocellular; Culture Techniques; I | 1969 |
Methylation of mammalian DNA: studies on Novikoff hepatoma cells in tissue culture.
Topics: Animals; Carcinoma, Hepatocellular; Cell Line; Culture Techniques; Cytosine Nucleotides; DNA; Liver | 1969 |
Development of resistance of Novikoff hepatoma to 5-fluoro-2'-deoxyuridine.
Topics: Carbon Isotopes; Carcinoma, Hepatocellular; Culture Techniques; DNA, Neoplasm; Floxuridine; Liver Ne | 1970 |
Considerations in the development of a predictive system for cancer chemotherapy.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line; DNA; Floxuridine; Fluorouracil; Liver N | 1971 |
Biochemical approaches to prediction of response in solid tumors.
Topics: Adenocarcinoma; Antineoplastic Agents; Carbon Isotopes; Carcinoma, Hepatocellular; Carcinoma, Squamo | 1971 |
MOdified nucleosides of nuclear and nucleolar low molecular weight ribonucleic acid.
Topics: Adenine; Animals; Carcinoma, Hepatocellular; Cell Nucleolus; Cell Nucleus; Chromatography, Gel; Chro | 1972 |
Letter: On the source of "minor thymine" in DNA from a Novik off rat hepatoma cell line.
Topics: Animals; Carcinoma, Hepatocellular; Cell Line; Chromatography, Paper; Cytosine; Deamination; Deoxycy | 1973 |
Beta-aminoisobutyric acid, a new probe for the metabolism of DNA and RNA in normal and tumorous tissue.
Topics: Aminoisobutyric Acids; Animals; Carbon Radioisotopes; Carcinoma, Hepatocellular; Cytosine; DNA; DNA, | 1974 |
A comparison of the utilization of thymine and thymidine for the synthesis of DNA-thymine in Novikoff hepatoma cells.
Topics: Alkylating Agents; Carcinoma, Hepatocellular; Cells, Cultured; Deoxyadenosines; Deoxycytidine; Deoxy | 1974 |
Dihydrouracil dehydrogenase activity in normal, differentiating and regnerating liver and in hepatomas.
Topics: Animals; Carcinoma, Hepatocellular; Cell Count; Cell Division; Female; Liver; Liver Neoplasms; Liver | 1971 |
A new method for treatment of carcinoma of the breast and colon with 5-fluorouracil.
Topics: Adult; Aged; Breast Neoplasms; Chemical Phenomena; Chemistry; Colonic Neoplasms; Female; Fluorouraci | 1970 |